Skip to main content
. 2024 Sep 12;15:7638. doi: 10.1038/s41467-024-52068-0

Fig. 8. PKN 1/2 deletion in resident cardiac fibroblasts, not in cardiomyocytes, suppressed cardiac fibrosis in HFpEF.

Fig. 8

Fibrotic changes in left ventricles assessed using Picrosirius red staining at 10 weeks after combination exposure to HFD and L-NAME in Pdgfra-PKN1/2 WT and KO mice (a) and in cardiomyocyte-specific PKN1/2 (cmc-PKN1/2) WT and KO mice (b) (n = 6, biological replicates per group). ns, not significant; ****p < 0.0001. Fraction shortening examined using echocardiography at 0, 5, and 10 weeks after combination exposure to HFD and L-NAME in Pdgfra-PKN1/2 WT and KO mice (c) (n = 10, biological replicates per group) and in cmc-PKN1/2 WT and KO mice (d) (n = 6, biological replicates per group). ns, not significant. e Representative early diastolic mitral inflow velocity (top) and annular velocity (bottom). Mitral E and E’ waves (E/E’) ratio at 0, 5, and 10 weeks after combination exposure to HFD and L-NAME in Pdgfra-PKN1/2 WT and KO male mice (f) (n = 10, biological replicates per group), and in cmc-PKN1/2 mice WT and KO male mice (g) (n = 6, biological replicates per group). ns, not significant; ***p = 0.0006; ****p < 0.0001. h End-diastolic pressure-volume relationship (EDPVR) obtained by cardiac catheterization at 0 and 10 weeks after combination exposure to HFD and L-NAME in Pdgfra-PKN1/2 WT and KO mice (n = 6, biological replicates per group). ns, not significant; **p = 0.0035; ****p < 0.0001. i E/E’ at 0, 5, and 10 weeks after combination exposure to HFD and L-NAME in Pdgfra-PKN1/2 WT and KO female mice (n = 6, biological replicates per group). ns, not significant; ****p < 0.0001. Data are presented as the mean ± SEM and analyzed using two-way ANOVA followed by Tukey’s post hoc test (a–d, h), or with two-way repeated measures ANOVA followed by Bonferroni post hoc test (f, g, i). The data represent three independent experiments with similar results. Source data are provided as a Source Data file.